BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 36094435)

  • 1. Role of syndecan-4 in breast cancer pathophysiology.
    Onyeisi JOS; Lopes CC; Götte M
    Am J Physiol Cell Physiol; 2022 Nov; 323(5):C1345-C1354. PubMed ID: 36094435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. microRNA-140-3p modulates invasiveness, motility, and extracellular matrix adhesion of breast cancer cells by targeting syndecan-4.
    Onyeisi JOS; Greve B; Espinoza-Sánchez NA; Kiesel L; Lopes CC; Götte M
    J Cell Biochem; 2021 Oct; 122(10):1491-1505. PubMed ID: 34180077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell surface heparan sulfate proteoglycans control adhesion and invasion of breast carcinoma cells.
    Lim HC; Multhaupt HA; Couchman JR
    Mol Cancer; 2015 Jan; 14(1):15. PubMed ID: 25623282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Syndecan-1 (CD138) as a Pathogenesis Factor and Therapeutic Target in Breast Cancer.
    Sheta M; Götte M
    Curr Med Chem; 2021; 28(25):5066-5083. PubMed ID: 34191695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Syndecan-1 and syndecan-4 are overexpressed in an estrogen receptor-negative, highly proliferative breast carcinoma subtype.
    Baba F; Swartz K; van Buren R; Eickhoff J; Zhang Y; Wolberg W; Friedl A
    Breast Cancer Res Treat; 2006 Jul; 98(1):91-8. PubMed ID: 16636895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of syndecans, a heparan sulfate proteoglycan, in malignant gliomas: participation of nuclear factor-kappaB in upregulation of syndecan-1 expression.
    Watanabe A; Mabuchi T; Satoh E; Furuya K; Zhang L; Maeda S; Naganuma H
    J Neurooncol; 2006 Mar; 77(1):25-32. PubMed ID: 16132527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Syndecan-4 as a Pathogenesis Factor and Therapeutic Target in Cancer.
    Onyeisi JOS; Lopes CC; Götte M
    Biomolecules; 2021 Mar; 11(4):. PubMed ID: 33810567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulated shedding of syndecan-1 and -4 ectodomains by thrombin and growth factor receptor activation.
    Subramanian SV; Fitzgerald ML; Bernfield M
    J Biol Chem; 1997 Jun; 272(23):14713-20. PubMed ID: 9169435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mapping of matrix metalloproteinase cleavage sites on syndecan-1 and syndecan-4 ectodomains.
    Manon-Jensen T; Multhaupt HA; Couchman JR
    FEBS J; 2013 May; 280(10):2320-31. PubMed ID: 23384311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Syndecan-1 modulates β-integrin-dependent and interleukin-6-dependent functions in breast cancer cell adhesion, migration, and resistance to irradiation.
    Hassan H; Greve B; Pavao MS; Kiesel L; Ibrahim SA; Götte M
    FEBS J; 2013 May; 280(10):2216-27. PubMed ID: 23289672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Syndecan-3 and perlecan are differentially expressed by progenitors and mature oligodendrocytes and accumulate in the extracellular matrix.
    Winkler S; Stahl RC; Carey DJ; Bansal R
    J Neurosci Res; 2002 Aug; 69(4):477-87. PubMed ID: 12210841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heparan sulfate chains of syndecan-1 regulate ectodomain shedding.
    Ramani VC; Pruett PS; Thompson CA; DeLucas LD; Sanderson RD
    J Biol Chem; 2012 Mar; 287(13):9952-9961. PubMed ID: 22298773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Innate immune signaling induces expression and shedding of the heparan sulfate proteoglycan syndecan-4 in cardiac fibroblasts and myocytes, affecting inflammation in the pressure-overloaded heart.
    Strand ME; Herum KM; Rana ZA; Skrbic B; Askevold ET; Dahl CP; Vistnes M; Hasic A; Kvaløy H; Sjaastad I; Carlson CR; Tønnessen T; Gullestad L; Christensen G; Lunde IG
    FEBS J; 2013 May; 280(10):2228-47. PubMed ID: 23374111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Syndecan-1-mediated cell spreading requires signaling by alphavbeta3 integrins in human breast carcinoma cells.
    Beauvais DM; Rapraeger AC
    Exp Cell Res; 2003 Jun; 286(2):219-32. PubMed ID: 12749851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heparan Sulfate Proteoglycans in Human Colorectal Cancer.
    Vicente CM; da Silva DA; Sartorio PV; Silva TD; Saad SS; Nader HB; Forones NM; Toma L
    Anal Cell Pathol (Amst); 2018; 2018():8389595. PubMed ID: 30027065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Syndecan-1 and syndecan-4 are independent indicators in breast carcinoma.
    Lendorf ME; Manon-Jensen T; Kronqvist P; Multhaupt HA; Couchman JR
    J Histochem Cytochem; 2011 Jun; 59(6):615-29. PubMed ID: 21430259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer.
    Davies EJ; Blackhall FH; Shanks JH; David G; McGown AT; Swindell R; Slade RJ; Martin-Hirsch P; Gallagher JT; Jayson GC
    Clin Cancer Res; 2004 Aug; 10(15):5178-86. PubMed ID: 15297422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Syndecan-1 signals independently of beta1 integrins during Raji cell spreading.
    Lebakken CS; McQuade KJ; Rapraeger AC
    Exp Cell Res; 2000 Sep; 259(2):315-25. PubMed ID: 10964499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth factor-induced shedding of syndecan-1 confers glypican-1 dependence on mitogenic responses of cancer cells.
    Ding K; Lopez-Burks M; Sánchez-Duran JA; Korc M; Lander AD
    J Cell Biol; 2005 Nov; 171(4):729-38. PubMed ID: 16286510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heparanase degrades syndecan-1 and perlecan heparan sulfate: functional implications for tumor cell invasion.
    Reiland J; Sanderson RD; Waguespack M; Barker SA; Long R; Carson DD; Marchetti D
    J Biol Chem; 2004 Feb; 279(9):8047-55. PubMed ID: 14630925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.